Announcement from Össur
hf. No. 55/2016
Reykjavík, 23 May 2016
On 3 December 2015, Össur hf. initiated a share buy-back program, see Company announcement no. 48/2015.
The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 1 December 2016. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million (approx. DKK 70 million).
The following transactions have been made under the program in the period 16 May 2016 - 20 May 2016:
|Date||No. of shares||Avg. purchase price DKK||Transaction Value DKK|
|16 May 2016||-||-||-|
|17 May 2016||15,561||25.80||401,536|
|18 May 2016||23,083||25.79||595,227|
|19 May 2016||13,702||25.74||352,624|
|20 May 2016||5,722||25.75||147,341|
Össur has acquired 1,079,334 shares under the program at the average price of DKK 24.08 Following the above transactions Össur's holding of own shares is 5,637,307 corresponding to 1.27% of the Company's total share capital.
The share buyback program on NASDAQ Copenhagen is carried out in compliance with the provisions of the European Commission's Regulation No. 2273/2003 ("the Safe Harbor Regulation").
Jón Sigurðsson, President & CEO Tel: +354 515 1300
Sveinn Sölvason, CFO Tel: +354 515 1300
Össur press releases by e-mail
If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings
Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com
This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.